-- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting ---- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 --BOSTON, May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter en ...